05/09/2026
Our groundbreaking Alzheimer’s trial is making national headlines.
Today, the PrevenTRON study at Surrey and Borders Partnership is the main story on the front page of The Daily Telegraph, alongside coverage from BBC News and the Daily Mail.
Surrey and Borders Partnership NHS Foundation Trust is the first site in Europe, and only the third in the world, to offer adults the opportunity to take part in the phase III PrevenTRON study.
The study will investigate whether the new drug Trontinemab can delay or prevent Alzheimer’s disease in people at high risk – before memory and thinking problems begin.
Professor Ramin Nilforooshan, Consultant Psychiatrist and Chief Investigator for PrevenTRON, said: “Being the first site across Europe and the third in the world to open PrevenTRON is a proud moment for our Research and Development team and for the communities we serve.”
Around 1,600 people aged 55 to 80 will take part worldwide, and as the lead UK recruitment site, we can recruit people from anywhere in the country.
Find out more about the study and how to get involved: https://bit.ly/4xaMQCT